These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16739917)

  • 1. [Quantitative structure-activity relationships of cyclin-dependent kinase 1 inhibitors].
    Zakharov AV; Lagunin AA; Filimonov DA; Poroĭkov VV
    Biomed Khim; 2006; 52(1):3-18. PubMed ID: 16739917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
    Ducrot P; Legraverend M; Grierson DS
    J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors.
    Mor M; Rivara S; Lodola A; Lorenzi S; Bordi F; Plazzi PV; Spadoni G; Bedini A; Duranti A; Tontini A; Tarzia G
    Chem Biodivers; 2005 Nov; 2(11):1438-51. PubMed ID: 17191945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
    Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
    J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
    Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
    Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QNA-based 'Star Track' QSAR approach.
    Filimonov DA; Zakharov AV; Lagunin AA; Poroikov VV
    SAR QSAR Environ Res; 2009 Oct; 20(7-8):679-709. PubMed ID: 20024804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
    Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
    J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases.
    Politi A; Durdagi S; Moutevelis-Minakakis P; Kokotos G; Papadopoulos MG; Mavromoustakos T
    Eur J Med Chem; 2009 Sep; 44(9):3703-11. PubMed ID: 19410337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds.
    Caballero J
    J Mol Graph Model; 2010 Nov; 29(3):363-71. PubMed ID: 20863730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents.
    Vyas VK; Bhatt HG; Patel PK; Jalu J; Chintha C; Gupta N; Ghate M
    SAR QSAR Environ Res; 2013; 24(7):519-51. PubMed ID: 23305412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of antimalarial activity of synthetic prodiginines: QSAR, GUSAR, and CoMFA analyses.
    Masand VH; Mahajan DT; Patil KN; Hadda TB; Youssoufi MH; Jawarkar RD; Shibi IG
    Chem Biol Drug Des; 2013 Apr; 81(4):527-36. PubMed ID: 23279875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
    Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
    J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
    Vaidya M; Weigt M; Wiese M
    Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of methods for modeling quantitative structure-activity relationships.
    Sutherland JJ; O'Brien LA; Weaver DF
    J Med Chem; 2004 Oct; 47(22):5541-54. PubMed ID: 15481990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
    Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
    Patel MR; Talele TT
    Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.